Use of DNA Microarray and Small Animal Positron Emission Tomography in Preclinical Drug Evaluation of RAF265, a Novel B-Raf/VEGFR-2 Inhibitor  by Tseng, Jeffrey R. et al.
Use of DNA Microarray and
Small Animal Positron Emission
Tomography in Preclinical Drug
Evaluation of RAF265, a Novel
B-Raf/VEGFR-2 Inhibitor1,2
Jeffrey R. Tseng*, Darrin Stuart†, Kimberly Aardalen†,
Angelo Kaplan‡, Natasha Aziz§, Nicholas P. Hughes*
and Sanjiv S. Gambhir*,¶
*Molecular Imaging Program at Stanford, Bio-X Program,
and Department of Radiology, Stanford University,
Stanford, CA, USA; †Department of Pharmacology,
Novartis Institutes for Biomedical Research, Emeryville, CA,
USA; ‡Department of Experimental Pathology, Novartis
Institutes for Biomedical Research, Emeryville, CA, USA;
§Department of Translational Biology, Novartis Institutes for
Biomedical Research, Emeryville, CA, USA; ¶Department of
Bioengineering, Stanford University, Stanford, CA, USA
Abstract
Positron emission tomography (PET) imaging has become a useful tool for assessing early biologic response to can-
cer therapy and may be particularly useful in the development of new cancer therapeutics. RAF265, a novel B-Raf/
vascular endothelial growth factor receptor-2 inhibitor, was evaluated in the preclinical setting for its ability to inhibit
the uptake of PET tracers in the A375M (B-RafV600E) humanmelanoma cell line. RAF265 inhibited 2-deoxy-2-[18F]fluoro-
D-glucose (FDG) accumulation in cell culture at 28 hours in a dose-dependent manner. RAF265 also inhibited FDG
accumulation in tumor xenografts after 1 day of drug treatment. This decrease persisted for the remaining 2 weeks
of treatment. DNA microarray analysis of treated tumor xenografts revealed significantly decreased expression of
genes regulating glucose and thymidine metabolism and revealed changes in apoptotic genes, suggesting that the
imaging tracers FDG, 3-deoxy-3-[18F]fluorothymidine, and annexin V could serve as potential imaging biomarkers for
RAF265 therapy monitoring. We concluded that RAF265 is highly efficacious in this xenograft model of human mela-
noma and decreases glucose metabolism as measured by DNA microarray analysis, cell culture assays, and small
animal FDG PET scans as early as 1 day after treatment. Our results support the use of FDG PET in clinical trials with
RAF265 to assess early tumor response. DNA microarray analysis and small animal PET studies may be used as
complementary technologies in drug development. DNAmicroarray analysis allows for analysis of drug effects onmul-
tiple pathways linked to cancer and can suggest corresponding imaging tracers for further analysis as biomarkers of
tumor response.
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Introduction
RAF265 is a novel, orally dosed, small-molecule B-Raf kinase and
vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitor
with potent antitumor activity in mutant B-Raf tumor models and is
currently undergoing phase 1 clinical trials in melanoma [1,2]. Inhibit-
ing mutant B-Raf as well as VEGFR-2 provides a dual mechanism of
action: antiproliferative activity by inhibiting the Ras/Raf/mitogen-
activated protein kinase (MAPK) pathway and indirect antitumor
activity by inhibiting angiogenesis through VEGFR-2.
2′-Deoxy-2′-[18F]fluoro-D-glucose positron emission tomography
(FDG PET) is a widely used clinical imaging test for many cancers
and for a wide range of indications [3]. Small animal PET scanners
for rodents [4] has allowed for the assessment of tumor xenograft
mouse models with FDG for preclinical oncology research and drug
development [5–9]. Several authors have used small animal FDG
PET to assess various therapies in mouse tumor xenograft models with
FDG and the proliferation tracer 3′-deoxy-3′-[18F]fluorothymidine
(FLT) [10–17]. We have recently shown that small animal PET stud-
ies are reproducible with moderately low variability, such that serial
studies on mouse tumor xenografts are reliable in assessing therapy
response [18,19].
DNA microarray analysis is a powerful technique to evaluate the
expression of thousands of genes in a single experiment. Recent stud-
ies in clinical oncology have used DNA microarray analysis for iden-
tifying cancer subtypes, predicting prognosis, predicting therapy
response, and understanding cancer biology [20,21]. Recently, several
groups have begun to investigate the combination of FDG PET and
DNA microarray analysis by correlating imaging findings with gene
expression changes [22–27]. The two technologies are complementary
and may provide unique insights into tumor biology. DNA microarray
analysis of gene expression allows for analysis of multiple genes and
multiple pathways but is limited by the need for invasive tissues sam-
pling and may be restricted to a single time point. FDG PET is a non-
invasive technology that allows for evaluation at multiple time points
in the same subject without the need for invasive pathologic exami-
nation; however, it is limited to analysis of a single pathway, namely
glucose metabolism albeit a very useful one for most cancers.
In this study, our first objective was to use DNA microarray analysis
to suggest pathways affected by RAF265, which have corresponding
imaging agents that could potentially serve as imaging biomarkers.
Our second objective was to assess whether small animal FDG PET
could be used to assess the efficacy of RAF265 in the A375M (B-
RafV600E) mouse xenograft tumormodel.We show that RAF265 inhib-
ited the glucose metabolism pathway and was confirmed by inhibition
of FDG accumulation both in cell culture and in tumor xenografts.
Materials and Methods
Pharmaceutical
RAF265 (Novartis, Emeryville, CA) is a novel, orally bioavailable,
small-molecule inhibitor of Raf kinase/VEGFR-2 with a molecular
weight of 518 g/mol. For cell culture experiments, the drug was dis-
solved in dimethyl sulfoxide. For in vivo mouse xenograft experiments,
the drug was dissolved in polyethylene glycol-400 (PEG-400) to a con-
centration of 25 mg/ml.
Cell Culture
A375M human melanoma cells, which express B-RafV600E, were
grown in minimum essential medium with Earle salts and L-glutamine,
supplemented with 10% fetal bovine serum, 1 mM sodium pyruvate,
and 1× nonessential amino acids (Mediatech, Manassas, VA). MV4;11
human acute myelogenous leukemia cells, which express wild-type B-
Raf, were grown in IscovemodifiedDulbeccomediumwith L-glutamine
and 25 mM HEPES, supplemented with 10% fetal bovine serum and
5 ng/ml granulocyte macrophage colony-stimulating factor. Cells were
grown at 37°C with 5% CO2 in a humidified incubator. For xeno-
graft implantation, cells were resuspended in Hank’s balanced salt
solution (Mediatech).
Cell Culture FDG, FLT, and Proliferation Assays
Fifty thousand A375M or MV4;11 cells were plated overnight onto
24-well plates. After changing the medium, 1.0 μM RAF265, 0.1 μM
RAF265, or no drug (solvent control) was added to the wells in trip-
licate and incubated for 4 to 5 hours and 24 to 28 hours. Approxi-
mately 1 μCi of FDG (PETNET or Stanford Radiochemistry Facility)
was added and incubated for 2 hours. Cells were rinsed with cold
phosphate-buffered saline (Invitrogen, Carlsbad, CA) and then lysed
with 1 N NaOH. Half of the sample was counted for radioactivity
using a Cobra II gamma counter (Packard, Meriden, CT). The re-
maining sample was used to determine protein concentration with a
Bradford protein assay (Bio-Rad, Hercules, CA). FDG accumulation
was calculated as: FDG accumulation (%/mg) = FDG activity within
the cells (cpm) ÷ total FDG added to the sample (cpm) ÷ total
protein (mg) × 100%. FLT assays for A375M cells were performed
in a similar manner using a 1-hour incubation period for FLT accu-
mulation. FLT was synthesized by the Stanford Radiochemistry
Facility with a specific activity greater than 45 TBq/mmol [18]. Pro-
liferation assays on cell lines were performed by incubating cells with
RAF265 diluted in complete medium over a concentration range of
0.1 to 20 μM in 96-well plates. After 72 hours of incubation, cells
were rinsed, and then the CellTiter-Glo assay was carried out as
described by the manufacturer (Promega, Madison, WI).
Mouse Xenograft Model for Tumor DNA Microarray Analysis
Animal protocols were approved by the Stanford Administrative
Panel on Laboratory Animal Care and the Novartis Institutional An-
imal Care and Use Committee. Forty-five 8-week-old nu/nu mice
(Charles River Laboratory) were injected subcutaneously with 3 mil-
lion A375M cells in the right flank. After approximately 1 week
when xenografts reached a size of approximately 200 mm3, five mice
were killed immediately as baseline controls (day 0). Tumors were har-
vested and frozen. The remaining mice were separated into groups of
five. Half of the groups were orally dosed with 100 mg/kg of RAF265
(approximate volume of 100 μl) every 2 days for 14 days. The other
half were orally dosed with vehicle PEG-400. Mice were killed, and
tumors were harvested at 8 hours, day 1, day 8, and day 14.
RNA was extracted from the tumor xenografts using an RNeasy kit
(Qiagen). Complementary DNA and RNA were synthesized. Comple-
mentary RNA was labeled and hybridized to a human genome U133
Plus 2.0microarray (Affymetrix, Santa Clara, CA). Data were normalized
using the MAS 5.0 software (Affymetrix).
The Gene Set Enrichment Analysis (GSEA) method [28,29] was
used to identify coordinate changes in biologic pathways modulated
by RAF265. The effects of RAF265 versus vehicle at each of the four
time points were mapped to 4014 publicly available pathways (KEGG
[Kanehisa Laboratories, Kyoto, Japan; n = 361 pathways], Panther
[SRI International, Palo Alto, CA; n = 1698 pathways], and Metacore
pathways [GeneGo, St Joseph, MI; n = 1955]) using an in-house
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implementation of GSEA as previously described [30]. A subset of
those results including pathways with corresponding molecular tracers
available is presented. Thirty-four major reference pathways for apop-
tosis (apoptosis/annexin V) or containing glucose transporters and/
or hexokinases (Entrez Gene IDs 6513, 6514, 6515, 6517, 6518,
11182, 155184, 29988, 56606, 81031, 66035, 154091, 114134,
144195, 3098, 3099, 3101, 2645), thymidine kinase (Gene ID
7083), and epidermal growth factor receptor (EGFR; Gene ID
1956) were identified (Table W1). Pathways considered significantly
modulated by RAF265 had a q value (reflecting the false discovery
rate) ≤ 1 × 10−5 [31].
Mouse Xenograft Model for Small Animal FDG PET
A separate group of forty 8-week-old female nu/nu mice was in-
jected subcutaneously with 3 million A375M cells in the right upper
flank. When tumors reached an approximate volume of 100 mm3,
eight mice were selected for cohort 1 (n = 4 control; n = 4 drug-treated
group). When tumors reached an approximate volume of 200 mm3,
12 mice were selected for cohort 2 (n = 6 control; n = 6 drug-treated
group). Mice were weighed, and tumors were measured with digital
calipers every 2 to 3 days. Tumors volumes were calculated using or-
thogonal measurements as length × width × width ÷ 2.
The drug dosing and imaging schedules were as follows. Mice were
administered 100 mg/kg RAF265 or vehicle (100% PEG-400) by oral
gavage every 3 days starting on day 0 and continuing to day 15. For
cohort 1 (starting tumor volume = 100 mm3), a day 0 baseline small
animal FDG PET scan was performed immediately before the first
drug dose, followed by imaging on days 1, 4, 7, 11, and 13. For cohort
2 (starting tumor volume = 200 mm3), mice were imaged on days 0,
1, 4, 7, 9, 10 or 11, 14, and 16. On day 9, imaging was performed
before dosing. Owing to the limited availability of tracer, only four mice
were scanned on days 9, 14, and 16 for the control group of cohort 2.
Data for day 10 or 11 were combined and analyzed together using a
middle time point of 10.5 days. One mouse in the drug-treated group
of cohort 2 died during scanning on Day 11, thereafter only three
mice were scanned on days 14 and 16 for the drug-treated group of
cohort 2. The mouse that died had no overt signs of toxicity, such as
illness, distress, or significant weight loss. In our experience, a death
rate of approximately 1% during scanning is expected, which may be
related to anesthesia, tumor burden, repeated tail injections, or a
combination of these factors. The single mouse death was most likely
related to scanning factors rather than drug toxicity. No body weight
loss or other toxicity was observed in the remaining mice.
Small Animal FDG PET Imaging
Imaging was performed as previously described and summarized
below [18,19]. After a 4- to 6-hour fast, approximately 200 μCi
of FDG was injected through the tail vein. One hour after injection,
a 7-minute static prone scan was obtained in a MicroPET R4
(Siemens/CTI, Munich, Germany) without partial volume correction
[32]. A sample three-dimensional rendering of a tumor-bearing mouse
is included as Figure W1.
Small Animal FDG PET Image Analysis
Ellipsoidal regions of interest (ROIs) were drawn around the edge of
the tumor activity using AMIDE software [33]. The mean, the mean
of the upper 20% of voxels, and the maximum activities were re-
corded. Percent injected dose per gram (%ID/g) and standardized up-
take value (SUV) were calculated as follows: %ID/g = ROI activity ÷
injected dose. SUV = ROI activity ÷ injected dose × body weight. Two
separate 5-mm background ROIs were drawn from the muscle adja-
cent to the tumor and in the opposite flank. Tumor-to-background
ratios were calculated.
Immunohistochemistry
Immunohistochemistry staining was performed on a separate set of
tumors treated with a similar drug regimen. Hematoxylin and eosin
(H & E) staining was performed to assess areas of viable tissue and
necrosis. Ki-67 staining was performed to assess areas of proliferation.
Statistical Analysis
For cell culture and small animal FDG PET studies, t tests were
performed to assess for significant differences between two groups of
data. For a comparison among three groups of data, analysis of var-
iance was first performed. If the analysis of variance was significant,
pairwise comparisons were then performed. P < .05 was chosen to
indicate significance. Data were reported with SEM error bars or
error values.
Results
RAF265 Inhibits Glucose and Thymidine Metabolism Gene
Expression as Determined by DNA Microarray Analysis
A pathway-based analysis of gene expression in A375M xenografts
from mice treated with RAF265 showed that RAF265 had profound
inhibitory effects on the cell cycle at all time points examined (data
not shown). Consistent with this, glucose metabolism, thymidine
metabolism, and apoptosis pathways were modulated by RAF265
(Table 1 and Figure 1). A summary diagram of effects of RAF265
on the glucose metabolism pathway is provided in Figure W2. EGFR
pathways were not transcriptionally modulated byRAF265 (TableW1).
This suggested that FDG (glucose metabolism), FLT (thymidine me-
tabolism), and annexin V (apoptosis) tracers may be useful in RAF265
imaging studies.
RAF265 Inhibits FDG Accumulation in A375M Cell Culture
A375M cells were incubated with two different concentrations of
RAF265 for 5 and 28 hours then assayed for FDG accumulation. At
28 hours, RAF265 treatment resulted in a significant dose-dependent
inhibition of FDG accumulation compared with controls (untreated
cells; Figure 2A). At 1.0 μM, RAF265 had a more significant decline
in FDG accumulation (75.5%, P = .0003) compared with the lower
concentration of 0.1 μM (38.2%, P = .02) compared with control.
At the earlier 5-hour time point, RAF265 did not show significant
inhibition. These results are consistent with potent antiproliferative
activity of RAF265 in these cells (IC50 = 0.28 μM).
To determine whether the effect of RAF265 was selective for cells
expressing mutant B-Raf, FDG accumulation was also evaluated in
the human acute monocytic leukemia cell line MV4;11, which ex-
presses wild-type B-Raf. At 4 and 24 hours, FDG accumulation in
drug-treated MV4;11 cells was not significantly different from con-
trol at both 1.0 and 0.1 μM (Figure 2B). These results were consis-
tent with the lack of antiproliferative activity of RAF265 on these
cells (IC50 = 6 μM).
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Figure 1. Scatter plot representation of pathways modulated by RAF265 in A375M xenografts. The effects of RAF265 (y-axis in each
scatter plot) versus vehicle (x-axis) on selected individual biologic pathways from Table 1 (pyrimidine metabolism [Pathway ID
map00240], carbohydrates metabolism [Pathway ID S8], apoptosis [Pathway ID 131161]) significantly modulated by RAF265 are shown
at selected time points. The relative expression of all probe sets (gray dots) and gene set–specific probe sets (blue dots) are indicated
(log-log scale).
Table 1. Pathways Modulated by RAF265 in A375M Xenografts.
Time Point Rank Pathway Pathway Data Source Pathway ID Pathway Name No. Probe Sets P q
Day 1: 8 h 32 Thymidine KEGG Pathways map00240 Pyrimidine metabolism — Reference pathway 83 1.17e − 12 8.07e − 11
Day 1: 8 h 69 Glucose MetaCore Pathway Maps S8 Carbohydrates metabolism 264 3.11e − 08 1.09e − 06
Day 1: 8 h 75 Thymidine MetaCore Pathway Maps S11 Nucleotide metabolism 224 2.45e − 07 7.46e − 06
Day 1: 24 h 45 Glucose MetaCore Pathway Maps S8 Carbohydrates metabolism 264 5.05e − 09 2.07e − 07
Day 1: 24 h 61 Thymidine KEGG Pathways map00240 Pyrimidine metabolism — Reference pathway 83 2.69e − 08 8.38e − 07
Day 1: 24 h 76 Apoptosis MetaCore Pathway Maps S121 Apoptosis and survival 242 1.20e − 07 3.10e − 06
Day 8 35 Thymidine KEGG Pathways map00240 Pyrimidine metabolism — Reference pathway 83 7.11e − 15 3.74e − 13
Day 8 66 Thymidine MetaCore Pathway Maps S11 Nucleotide metabolism 224 4.15e − 11 1.25e − 09
Day 8 122 Glucose MetaCore Pathway Maps 930 Glycolysis and gluconeogenesis (short map) 33 8.63e − 08 1.40e − 06
Day 8 132 Glucose MetaCore Pathway Maps S8 Carbohydrates metabolism 264 2.14e − 07 3.23e − 06
Day 8 141 Apoptosis MetaCore GeneGo Processes 131161 Apoptosis_Apoptotic mitochondria 85 3.44e − 07 4.88e − 06
Day 14 33 Thymidine KEGG Pathways map00240 Pyrimidine metabolism — Reference pathway 83 8.88e − 16 4.29e − 14
Day 14 65 Thymidine MetaCore Pathway Maps S11 Nucleotide metabolism 224 1.82e − 12 5.28e − 11
Day 14 96 Apoptosis MetaCore Pathway Maps S121 Apoptosis and survival 242 4.95e − 10 9.88e − 09
Day 14 133 Glucose PANTHER Library and Pathways MF00109 Carbohydrate kinase 26 2.73e − 08 3.95e − 07
Day 14 151 Apoptosis MetaCore GeneGo Processes 131161 Apoptosis_Apoptotic mitochondria 85 6.23e − 08 8.02e − 07
Day 14 156 Glucose MetaCore Pathway Maps S8 Carbohydrates metabolism 264 7.28e − 08 9.07e − 07
Day 14 163 Glucose MetaCore Pathway Maps 930 Glycolysis and gluconeogenesis (short map) 33 1.31e − 07 1.55e − 06
Reference pathways modulated by RAF265 (q ≤ 1 × 10−5) and containing genes relevant to FDG (glucose), FLT (thymidine), annexin V (apoptosis), and EGFR tracer modalities are indicated. Time of
RAF265 or vehicle control treatment (Time Point), the rank (by q value) of pathway within a time point (4014 pathways evaluated per time point), source of gene pathway (Pathway Data Source),
pathway reference number (Pathway ID), name for the pathway used by the Pathway Data Source (Pathway Name), number of probe sets analyzed for each pathway (No. Probe Sets), P value, and q value
are indicated. GSEA results are in Table W1.
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RAF265 Inhibits FLT Accumulation in A375M Cell Culture
The DNA microarray data indicating inhibition of thymidine ki-
nase containing pathways by RAF265 suggested that RAF265 should
also inhibit the uptake of FLT. Therefore, A375M cells were incubated
with two different concentrations of RAF265 for 4 and 24 hours then
assayed for FLT accumulation. At the earlier 4-hour time point,
RAF265 did not significantly inhibit the uptake of FLT; however,
by 24 hours, there was a significant decrease in FLT accumulation at
1.0 μM (P < .0001) but not at 0.1 μM (P = .24; Figure 2C ). Because
FLT inhibition was only significant at the higher dose of RAF265
and only at 24 hours compared with FDG, it was concluded that
FDG may be a slightly more sensitive tracer as an imaging biomarker
to test in an in vivo tumor xenograft model. No further testing was
performed with FLT.
RAF265 Inhibits FDG Accumulation in A375M Xenografts
Nude mice with A375M tumor xenografts were dosed orally with
100 mg/kg RAF265 every 3 days at two different starting tumor vol-
umes of 100 mm3 for cohort 1 and 200 mm3 for cohort 2 (Figure 3A).
Tumor volumes for the control mice increased two- to three-fold dur-
ing the study, whereas the tumor volumes decreased 51.0% and
35.1% for drug-treated cohorts 1 and 2, respectively.
FDG accumulation was assessed during 2 weeks in the same mice.
Representative small animal FDG PET images for a RAF265-treated
mouse (Figure 4A) and a control mouse (Figure 4B) revealed inhibi-
tion of FDG accumulation by RAF265. For the RAF265-treated
mice in cohort 1 (Figure 3B), the mean %ID/g of FDG accumula-
tion decreased 28.2% on day 1 compared with the baseline day 0 and
showed a statistically significant difference compared with the cohort
1 control group (P = .0001). The FDG accumulation continued to
decrease for the drug-treated group, reaching a maximum decrease of
51.0% at day 13. The drug-treated group remained significantly de-
creased from the control group at all time points after day 0.
For cohort 2, the mean %ID/g of FDG accumulation decreased in
the drug-treated group on day 1 by 30.9% compared with the base-
line day 0 (Figure 3B). FDG accumulation was significantly lower in
the drug-treated group than the control group on day 1 (P = .04) and
day 4 (P < .0001). After day 7, FDG accumulation was lower in the
control group compared with the RAF265-treated group. Visual in-
spection of the images revealed central photopenia, suggestive of tu-
mor necrosis, in tumors greater than approximately 300 mm3. As the
tumors increased in size, the central photopenia also increased (Fig-
ure 4C ). Visual inspection of excised tumors suggested central ne-
crosis in the larger tumors. This observation may partly explain the
decrease in the mean %ID/g over time for the control tumors. To con-
firm, tissue sections of a representative tumor from a mouse under a
similar dosing schedule also showed tumor necrosis with H & E stain-
ing and corresponding areas of decreased proliferation with Ki-67
staining (Figure 5).
Analysis of the max %ID/g, upper 20% %ID/g, SUV, and tumor-
to-background ratios produced similar results and statistical signifi-
cance to the mean %ID/g analysis (data not shown). Analysis of data
normalized to the baseline day 0 was also similar.
Comparison of FDG Accumulation versus Tumor Volume
To assess the early response to RAF265, day 1 data were further
analyzed. Compared with baseline, FDG accumulation decreased
28.2% and 30.9% for cohorts 1 and 2, whereas tumor volumes de-
creased only 14.9% and 5.2%, respectively (Figure 3C ). In cohort 1,
both FDG accumulation (P = .0001) and tumor volume (P = .01)
were significantly different compared with controls; however, in
cohort 2, only FDG decreased significantly compared with control
(P = .04), whereas the decrease in tumor volume was not significant
Figure 2. Cell cultures were treated with two concentrations of
RAF265 drug for 5 and 28 hours and then assayed for FDG accu-
mulation. (A) FDG accumulation in A375M cells was inhibited
by RAF265 in a dose-dependent manner at 28 hours (black bars).
(B) There was no significant inhibition of FDG accumulation by
RAF265 inMV4;11 cells. (C) A375M cells were treatedwith two con-
centrations of RAF265 drug for 4 and 24 hours and then assayed for
FLT accumulation. RAF265 inhibited FLT accumulation at 24 hours
with the 1.0 μM RAF265 concentration. Error bars represent SEM.
P values according to t test for comparisons between RAF265 and
controls are indicated (*P < .05, **P < .01, and ***P < .001).
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(P = .25). This analysis supports the hypothesis that FDG accumu-
lation is an earlier, more sensitive measure of antitumor activity.
Discussion
In this study, our first objective was to use DNA microarray analysis
to select appropriate tracers for PET imaging. We assessed whether
changes in expression of genes involved in glucose metabolism, thy-
midine metabolism, apoptosis, or EGFR signaling could provide in-
sight into which PET tracers might be effective in melanoma by
performing a pathway-based analysis on DNA microarray data from
RAF265-treated A375M xenografts. RAF265 significantly modulated
glucose metabolism, pyrimidine metabolism, and apoptosis pathways,
Figure 3. (A) Tumor volume growth curves for A375M xenografts treated with 100 mg/kg RAF265 or PEG-400 (control) dosed every
3 days. Cohort 1 (left) had a starting tumor volume size of 100 mm3 (n = 4). Cohort 2 (right) had a starting tumor volume size of 200 mm3
(n = 6). Error bars represent SEM. P values according to t test for comparisons between RAF265 and vehicle control are indicated (*P <
.05, **P < .01, and ***P < .001). (B) Mean %ID/g FDG accumulation assayed with small animal FDG PET. Cohort 1 (left) and cohort 2
(right) showed a significant decrease in FDG accumulation for the RAF265 drug-treated groups compared with the control groups as early
as day 1. (C) Comparison of tumor volume and FDG accumulation curves for the RAF265-treated A375M xenografts. Values are shown as
a percentage of the baseline day 0 value. The FDG accumulation curves indicate that there is a significantly greater fold reduction at
day 1 compared with the tumor volume for both cohorts. P values for comparisons relative to baseline day 0 are indicated (†P < .05
and †††P < .001).
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suggesting that FDG, FLT, and annexin V, but not EGFR-based im-
aging modalities, may have utility. The modulation of glucose metab-
olism was consistent with the subsequent results, demonstrating that
FDG accumulation was inhibited in cell culture and in the mouse tu-
mor xenograft model.
It will be interesting to examine cell accumulation and small animal
PET imaging for all four tracers in both cell lines and animal studies.
We plan to perform a larger study where several tracers are investigated
in several drug-resistant and drug-sensitive cell lines and xenografts to
establish a more comprehensive relationship between tracer efficacy
and changes in gene expression. It may be possible to correlate tracer
efficacy to gene expression changes using a much smaller cohort of
genes representing imaging-relevant biologic pathways. In this case,
the resource-intensive DNA microarray approach could be substituted
with interrogation of a panel of key genes by quantitative polymerase
chain reaction. Because RAF265 inhibits VEGF-induced angiogenesis
[34] as well as mutant B-Raf, angiogenesis pathways and new emerg-
ing tracers for imaging angiogenesis will also be investigated to assess
the relative strengths of the dual mechanism of action.
Our second objective was to determine whether FDG PET could
be used to assess the efficacy of RAF265. We first demonstrated that
RAF265 inhibited FDG accumulation in A375M human melanoma
cell culture in a dose-dependent manner (Figure 2A). We subsequently
demonstrated that RAF265 inhibited FDG accumulation in an A375M
mouse tumor xenograft model as early as 1 day of drug treatment
(Figure 3, B and C ) using small animal FDG PET. Significant effects
of RAF265 of FDG accumulation were observed before tumor vol-
ume changes and persisted during the entire 2 weeks of the experi-
ment. Furthermore, significant inhibition of FDG accumulation was
consistent with down-regulation of the genes involved in the uptake
and trapping of FDG, as assessed by gene expression analysis.
RAF265 is currently in phase 1 clinical trials for melanoma, and
we anticipate that clinical FDG PETwill play a central role in asses-
sing early response to treatment based on these preclinical results. We
are unaware of any published studies that have used small animal
FDG PET followed by validation with clinical FDG PET. This study
may serve as a model for how PET and molecular imaging can im-
prove the drug development process by validating imaging modalities
before initiation of phase 1 trials. Follow-up analysis will be per-
formed after the conclusion of phase 1 trials to determine the predic-
tive value of these preclinical studies.
Although few studies that used FDG PET for monitoring thera-
peutic response in clinical trials exist in the literature, we believe that
PET can and should be used to assess response to therapy based on
its proven utility in clinical practice [35]. FDG PETmay serve as an
exemplary marker in clinical trials of novel melanoma drugs based on
the ability of PET to follow therapy response in other tumors [36]
and based on the excellent ability of FDG PET to detect melanoma
Figure 4. Three-dimensional volume renderings of small animal FDG PET images of nude mice bearing A375M xenografts (arrows). (A)
Cohort 1 drug-treated tumor from baseline day 0 to day 13 of treatment with 100 mg/kg RAF265. By day 13, the activity had dramatically
decreased. (B) Cohort 1 control tumor from baseline day 0 to day 13 of treatment with vehicle (PEG-400). FDG accumulation gradually
increased over time. (C) Coronal small animal FDG PET images of an A375M mouse tumor xenograft from the control group of cohort 2
reveal the internal characteristics of the tumor. Images are displayed during 16 days with tumor sizes and mean %ID/g FDG accumu-
lation listed below. The tumor (arrows) showed increasing central necrosis for tumor sizes greater than 300 mm3.
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[37]. As an example, a small phase 2 trial of a novel polyamine syn-
thesis inhibitor showed that FDG PET was an early predictor of a
poor response in metastatic melanoma [38]. In addition, a recent
phase 1 dose-escalation trial of a mutant BRAF inhibitor showed
markedly decreased tumor FDG uptake at day 15 of treatment of
metastatic melanoma [39]. FDG PET could be invaluable in the
clinical development of novel targeted agents such as RAF265.
The current paradigm in dose determination for these agents is based
more on the optimal biologic dose rather than the traditional maxi-
mal tolerated dose [40]. A noninvasive method such as FDG PET
could be an excellent tool to determine the optimal biologic dose
and to assess tumor response for RAF265 in melanoma patients.
FDG PET has an advantage over anatomic imaging in that changes
in FDG accumulation can often be seen earlier than change in ana-
tomic size. In our study, we observed that changes in FDG accumu-
lation were larger and observed earlier compared with tumor volume
changes. These changes occurred on the time scale of days in the
mouse model, which may translate to a time scale of weeks for patients
or possibly sooner. The ability of FDG PET to see earlier changes may
significantly impact treatment decisions and survival. Our preclinical
imaging results are in agreement with previous work from our group
[13], others [17], and in clinical studies [41].
On the basis of these results, we propose a stepwise approach to
select a suitable imaging tracer for tumor evaluation. Gene expression
analysis is first performed on tumor cells treated with drug in vitro
to interrogate molecular pathways that have corresponding imaging
tracers. Pathways that are most affected will suggest which imaging
tracers can be used in subsequent tracer accumulation studies in cell
culture and small animal PET studies in mouse xenograft models.
In human clinical studies, the choice of an imaging biomarker for
cancer is limited to a few modalities. Most oncology studies are per-
formed with contrast enhanced computed tomography (CT) and/or
FDG PET/CT, with a few other imaging modalities for more spe-
cialized applications, such as contrast-enhanced magnetic resonance
imaging (MRI) for brain and musculoskeletal tumors, somatostatin
receptor imaging for neuroendocrine tumors, iodine 123 (123I) for
thyroid cancer, and [123I]metaiodobenzylguanidine for pheochromo-
cytoma. Many new imaging modalities and agents are in development,
such as whole-body diffusion-weighted MRI, [18F]fluoromisonidazole
PET for tumor hypoxia, and VEGFR imaging for angiogenesis [42–
44]. With the increasing availability of molecular imaging agents, the
selection of the most optimal tracer may be more challenging in the
future. Gene expression profiling has the potential to assist with the se-
lection of an appropriate imaging agent. To be useful, gene expression
analysis of changes in gene expression must be correlated with imaging
agent features. One revealing example was provided by the study of
Segal et al. [45], where CT imaging traits of liver tumors were corre-
lated with gene expression profiles. Other works have also been per-
formed to correlate gene expression profiles with FDG PET [22–27].
In the future, tailored or personalized imaging biomarkers through
rational selection may become more prevalent, much like personalized
therapies have been envisioned.
This article attempts to unite DNA microarray and small animal
PET analysis within the context of drug development and therapy
evaluation. The studies presented here provide a model for transla-
tional research using DNA microarray technology, cell culture assays,
and in vivo small animal PET studies, which can direct the selection
of an appropriate PET tracer for human clinical studies.
Figure 5. Magnified coronal small animal FDG PET images of vehicle-treated and RAF265-treated A375M tumor xenografts. Pathologic
staining with H & E shows areas of nonviable tumor and tumor necrosis. Pathologic staining with Ki-67 shows corresponding areas or
absence of tumor proliferation.
Neoplasia Vol. 13, No. 3, 2011 Microarray and Small Animal PET for RAF265 Tseng et al. 273
Conclusions
We would like to offer one specific conclusion regarding RAF265
and two general conclusions regarding DNA microarray analysis
and small animal PET. 1) RAF265 is an efficacious novel B-Raf/
VEGFR-2 inhibitor, which causes decreases in tumor glucose metab-
olism and FDG accumulation as early as 1 day after treatment in our
preclinical model. The small animal FDG PET results support the
decision to proceed with clinical trials and also support the use of
human clinical FDG PET to assess early tumor response in ongoing
phase 1 trials of RAF265 for melanoma. 2) DNA microarray analysis
and small animal PET are complementary technologies that can each
serve as a biomarker to assess glucose metabolism within the context
of drug development for drug evaluation. 3) DNA microarray anal-
ysis can screen multiple pathways involved in cancer. Significant
changes can be used to select corresponding molecular imaging
agents for further cell culture and in vivo evaluation.
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Figure W1. Rotating three-dimensional volume rendering of a small
animal FDG PET image of a typical nude mouse with an A375M
tumor xenograft in the right upper flank. The image was obtained
one hour after the injection of 200 μCi of FDG. Intense activity is
seen in the right upper flank at the site of the tumor xenograft. Nor-
mal intense physiologic activity is seen in the brain, heart, blad-
der, and kidneys. Mild physiologic activity is seen in the liver, bowel,
and muscles.
Figure W2. Regulation of glucose transport and glycolysis genes by RAF265. Genes involved in glucose transport and glycolysis (shaded
rectangles), glucose metabolism substrates (open rectangles), FDG metabolism substrates (dashed rectangles), and plasma membrane
(dark gray bar at the left) are indicated. Arrows indicate genes significantly downregulated in A375M xenografts after RAF265 treatment for
at least one time point (DNAmicroarray analysis, P< .05 with Bonferroni correction. One probe set with the greatest dynamic range across
all samples was evaluated for ALDOA, ALDOC, ENO1, ENO2, G6PC, G6PC3, G6PD, HK1, HK2, LDHA, LDHB, LDHC, PFKFB1, PFKFB2,
PFKFB3, PFKFB4, PFKP, PGK1, PGK2, PKM2, SLC2A1, SLC2A3, SLC2A5, SLC2A6).
